COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
29/10/2018
Full Antagonist Mechanism of Action Demonstrated In Vivo Long-term Control of Specific Memory T Cell Mediated Autoimmunity and Chronic Inflammation NANTES, France, Oct. 29, 2018 (GLOBE NEWSWIRE) -- OSE [...]
Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer
29/10/2018
Press Release Gosselies, Belgium, 29 October 2018, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, [...]
Bone Therapeutics annonce la nomination de Linda Lebon au poste de Chief Regulatory Officer
29/10/2018
Communiqué de presse Gosselies, Belgique, le 29 octobre 2018, 7h CET - BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non [...]
Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018
27/10/2018
Data supports further clinical evaluation of brincidofovir for the treatment and prevention of BK virus DURHAM, N.C., Oct. 27, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced data from two preclinical [...]
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
27/10/2018
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness [...]
Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
27/10/2018
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO, Oct. 26, 2018 (GLOBE NEWSWIRE) -- [...]
Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2018
27/10/2018
TORONTO, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”) , a specialty cannabis company focused on the research, development and [...]
Helix BioPharma Corp. Announces Fiscal 2018 Year-End Results
26/10/2018
RICHMOND HILL, Ontario, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its [...]
The Ensign Group Schedules Third Quarter 2018 Earnings Call for Thursday, November 1, 2018
26/10/2018
MISSION VIEJO, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home health care, hospice care [...]
Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
26/10/2018
BOSTON, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]
IntelGenx Announces Exercise of Over-Allotment Option
26/10/2018
SAINT LAURENT, Quebec, Oct. 26, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the “ Company ” or “ IntelGenx ”) announces that in connection with its previously announced public offering [...]
Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018
26/10/2018
BERKELEY, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the treatment of IgA [...]
Assurance Proves that an Engaging Work Culture Results in Happy Employees and a Great Place to Work
26/10/2018
SCHAUMBURG, Ill., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Assurance employees have a lot of praise about working at the insurance brokerage; praise that has landed the organization a win on the 100 Best Medium Workplaces list [...]
RadNet, Inc. Announces Date of its Third Quarter 2018 Financial Results Conference Call
26/10/2018
LOS ANGELES, Oct. 26, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
26/10/2018
GAITHERSBURG, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer will provide a [...]
CRUZANI Snack Innovation: The MondoChurro!™
26/10/2018
Proprietary twist on a popular favorite by CRUZANI Oventa Foods ATLANTA, Oct. 26, 2018 (GLOBE NEWSWIRE) -- CRUZANI, Inc. (OTC: CZNI), www.CRUZANI.com , a global business development company focused on creating and [...]
New Clinical Trial Demonstrates Efficacy and Safety of Vayarin® Plus for Adults with ADHD
26/10/2018
COLUMBIA, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and leader in developing specialty nutrition and medical food products, announced today that a new clinical trial [...]
Orion Corporation: Managers' transactions - Eija Ronkainen
26/10/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 26 OCTOBER 2018 at 17.00 EEST Orion Corporation: Managers' transactions - Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
26/10/2018
Late-Breaking Data Demonstrate Significant Association Between Higher ANAVEX®2-73 Concentration and Maintained Activities of Daily Living and Reduced Cognitive Decline in Alzheimer’s Disease Patients Data Confirm [...]

Pages